Vaccine against RSV

• US 10,456,462 B2
• Filed: 07/07/2016
• Issued: 10/29/2019
• Est. Priority Date: 07/07/2015
• Status: Active Grant

• Current Assignee: Janssen Vaccines & Prevention B.V. (Johnson & Johnson)
• Original Assignee: Janssen Vaccines & Prevention B.V. (Johnson & Johnson)
• Inventors: Langedijk, Johannes, Roymans, Dirk Andre Emmy
• Primary Examiner(s): Chen, Stacy B
• Application Number:
  US15/742,249
• Publication Number:
  US 20180200360A1
• Time in Patent Office: 1,209 Days
• Field of Search: None
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/155 Paramyxoviridae, e.g. parainfluenza virus
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.

Claims

1. A composition comprising a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein the polypeptide comprises SEQ ID NO:

21.

4. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 1.

2. A composition comprising a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein, as compared to a wild type RSV F polypeptide, the recombinant RSV F polypeptide comprises:

(i) a mutation of the amino acid at position 486 from aspartic acid (D) to asparagine (N), and

(ii) at least one of

a. a mutation of the amino acid residue at position 67 from asparagine (N) or threonine (T) to isoleucine (I), and

b. a mutation of the amino acid residue at position 215 from serine (S) to proline (P).

3. The composition of claim 2, wherein the recombinant RSV F polypeptide comprises:

(i) the mutation of the amino acid at position 486 from aspartic acid (D) to asparagine (N),

(ii) the mutation of the amino acid residue at position 67 from asparagine (N) or threonine (T) to isoleucine (I), and

(iii) the mutation of the amino acid residue at position 215 from serine (S) to proline (P).

5. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 2.

6. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 3.